Given these interactions between Notch and other cancer-related pathways, it is of great importance to study the combination therapies targeting Notch alongside PI3K/AKT/mTOR inhibitors, NF-κB deterrence, Her2/Neu targets, platinum-based chemotherapies, EGFR inhibitors, and Hh pathway suppressors [50]. This evidence concerns the gene MTOR and cancer.